Comparative pharmacokinetics of quercitrin, astragalin, afzelin and taxifolin in plasma after oral administration of Polygonum orientale inflorescence in sham-operated and myocardial ischemia–reperfusion injury rats

Abstract

1. The study aimed to compare the pharmacokinetic properties of quercitrin, astragalin, afzelin and taxifolin, four major bioactive components of Polygonum orientale inflorescence extracts, between sham-operated and myocardial ischemia–reperfusion injury (MIRI) rats.

2. Rats were divided into two groups: MIRI model and sham-operated. The blood samples were collected according to the time schedule. The levels of quercitrin, astragalin, afzelin and taxifolin in the plasma at designated time points were determined using an HPLC–MS/MS method. Various pharmacokinetic parameters were estimated from the plasma concentration versus time data using non-compartmental methods. After the administration of the Chinese herb Polygonum orientale inflorescence extracts, the C_max, AUC, as well as MRT, increased, while CL decreased, in MIRI model compared to the sham-operated animals.

3. These results suggest that the pathological damage of ischemia–reperfusion had a significant impact on the pharmacological effects of Polygonum orientale inflorescence extracts on ischemic heart disease.

4. The method had been successfully applied to evaluate the pharmacokinetics of quercitrin, astragalin, afzelin and taxifolin in rat plasma after the oral administration of Chinese herb Polygonum orientale inflorescence extracts in rats.

Keywords:

• Chinese herb
• Polygonum orientale inflorescence
• pharmacokinetics
• myocardial ischemia–reperfusion injury rats
• HPLC–MS/MS

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by the National Natural Science Foundation of China under Grant numbers (81560630, U1812403, 81360664); Guizhou Science and Technology Department under Grant numbers ([2019]5660/1439, [2018]4006, [2017]5601); and Guiyang Science and Technology Bureau under Grant number ([2017]30-29).